Home
Drugs
Fludarabine

Fludarabine

Drug

Drug Profile

Fludarabine is a purine analogue antineoplastic chemotherapy agent used for leukemia and lymphoma, including chronic lymphocytic leukemia. It is commonly administered as fludarabine phosphate by intravenous or oral routes. It was approved for medical use in the United States in 1991.

Drug Class: Purine analogue antimetabolite
Approval Status: Approved for medical use in the United States in 1991.
Mechanism of Action: Interferes with DNA duplication by inhibiting DNA synthesis through effects on ribonucleotide reductase and DNA polymerase.

Brand Names

Fludara
Oforta

Indications

\Chronic lymphocytic leukemia\
\Non-Hodgkin's lymphoma\
Leukemia

Related News

Off-the-Shelf CAR-T Therapy CB-011 Shows High Response Rates in Multiple Myeloma; Broader CAR-T Advances Presented at 2026 Tandem Meetings

Jun 09, 2026

Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.

Soft Tissue Sarcoma Pipeline Highlights Phase II and Late-Stage Programs

May 12, 2026

Soft tissue sarcoma pipeline activity includes 70+ companies and 75+ therapies. A phase II ADI-PEG 20 trial with gemcitabine and docetaxel was designed for sarcomas, while other 2026 studies span synovial sarcoma and unresectable advanced disease.

Multiple Myeloma Pipeline Expands With 80+ Therapies as Treatment Paradigms Evolve

Mar 20, 2026

The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.

CAR T-Cell Therapies Target BCMA and Alternative Antigens in Multiple Myeloma

Feb 28, 2026

New CAR T-cell approaches targeting BCMA and CD19 simultaneously show encouraging early results, while researchers develop control strategies for CAR-T therapies including antibody-drug conjugates.

FDA Approves Acalabrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia

Feb 23, 2026

The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.

FDA Approves Calquence Plus Venetoclax as First All-Oral Fixed-Duration CLL Treatment

Feb 20, 2026

FDA approves AstraZeneca's Calquence plus venetoclax as first all-oral, 14-month fixed-duration regimen for first-line chronic lymphocytic leukemia, with 77% of patients progression-free at three years in Phase III trial.

FDA Approves Acalabrutinib Plus Venetoclax for First-Line CLL and SLL Treatment

Feb 20, 2026

The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Venclexta and Acalabrutinib Combination for Previously Untreated CLL Patients

Feb 20, 2026

The FDA has approved a supplemental new drug application for the combination regimen of Venclexta (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY trial data.

FDA Approves Acalabrutinib Plus Venetoclax for Previously Untreated CLL

Feb 20, 2026

The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.

FDA Approves 46 Novel Drugs in 2025, Small Molecules Lead with 31 Approvals

May 01, 2025

The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07614048	Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS	TEMPORARILY_NOT_AVAILABLE
NCT07613788	Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL	NOT_YET_RECRUITING	PHASE2
NCT07613723	A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies	RECRUITING	PHASE1
NCT07604233	Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07598955	Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma	RECRUITING	PHASE1/PHASE2
NCT07593482	Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.	NOT_YET_RECRUITING	PHASE2
NCT07591649	Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT	RECRUITING	PHASE1/PHASE2
NCT07589543	Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer	RECRUITING	PHASE1/PHASE2
NCT07589530	Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors	RECRUITING	PHASE1/PHASE2
NCT07583303	BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation	NOT_YET_RECRUITING	PHASE1